With respect Suzuki, many have been patient here for a very long time, and financial governance issues still continue to be relevant to this day.
That the IP has progressed significantly from 2 years ago is undoubtedly true, WP said back then that one billion dollars plus could not buy the Company, that they had a internal valuation of $50 plus, suitors in the wings, that a NASDAQ listing would be done soonest, that commercialisation was set for two/three years ….. and add several CRs and the sp has done what for the last two years plus.
That commenting on this from an analytic angle on why this is what it is you refer to it as ‘bitching and moaning’ then so be it. If WP had tempered that spiel there could be what to ‘bitch’ about; we aim to have a internal valuation of $50 plus, we aim to create a one billion dollar plus Company, ect ect.
That is why I find it hard to believe anything he says regarding financial governance forecasts, maybe one day in this area the talk will match the walk.
Arguably you could say the Company was on the ropes thru failed business strategies initiated by WP/BOD from the Code Red period, were they based on the ‘cash flow positive’ assumption?
Vaccine R&D funding ceased, resulting in massive saving of future funds that could be directed towards the CardioCel R&D going forward.
I believe what, relatively, rerated the Company at the time as the FDA approval for the CardioCel IP, the Vaccines IP, initially, also did save the Company it that it attracted significant amounts of revenue that probably also contributed to the CardioCel R&D and the foundation for todays IP.
Yes the Vaccine part did become on the nose and I was disparaged for saying so and that something had to give in relation to its future.
Imho, not advice.
Expand
(20min delay)